ATR and cancer: Berzosertib (formerly M6620, VX-970, VE-822) is a selective and potent inhibitor of ataxia–telangiectasia and Rad3-related (ATR) for intravenous administration and is being developed in combination with chemotherapy for the treatment of patients with advanced cancers [1, 2].